We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $168M
1-Year Est. Return 60.36%
This Fund
S&P 500
This Quarter Est. Return
+21.23%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$248M
AUM Growth
+$27.4M
Cap. Flow
-$3.33M
Cap. Flow %
-1.34%
Top 10 Hldgs %
69.93%
Holding
98
New
13
Increased
15
Reduced
10
Closed
10

Top Buys

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$1.83M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$1.36M
3
CYTK icon
Cytokinetics
CYTK
+$1.24M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$985K
5
DAWN
Day One Biopharmaceuticals
DAWN
+$666K

Top Sells

Rank Stock Value
1
CLMT icon
Calumet Specialty Products
CLMT
+$7.4M
2
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$2.91M
3
INZY
Inozyme Pharma
INZY
+$2.66M
4
ESGR
Enstar Group
ESGR
+$2.52M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.5M

Sector Composition

Rank Sector Weight
1 Healthcare 34.94%
2 Materials 21.4%
3 Financials 15.49%
4 Communication Services 11.05%
5 Industrials 1.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNQ icon
51
Canadian Natural Resources
CNQ
$93.4B
$537K 0.22%
16,800
– –
XBI icon
52
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$501K 0.2%
5,000
+2,000
+67% +$180K
MDLZ icon
53
Mondelez International
MDLZ
$77.9B
$500K 0.2%
8,000
-1,000
-11% -$64.5K
OBIO icon
54
Orchestra BioMed
OBIO
$229M
$484K 0.2%
195,000
+95,000
+95% +$262K
FATE icon
55
Fate Therapeutics
FATE
$283M
$460K 0.19%
+365,000
New +$394K
XENE icon
56
Xenon Pharmaceuticals
XENE
$6.36B
$440K 0.18%
10,962
– –
JSPR icon
57
Jasper Therapeutics
JSPR
$23.1M
$408K 0.16%
+171,389
New +$520K
SRRK icon
58
Scholar Rock
SRRK
$5.86B
$335K 0.14%
+9,000
New +$315K
BIIB icon
59
Biogen
BIIB
$29.5B
$280K 0.11%
+2,000
New +$270K
BCRX icon
60
BioCryst Pharmaceuticals
BCRX
$2.43B
$247K 0.1%
32,570
-300,055
-90% -$2.5M
NVDA icon
61
NVIDIA
NVDA
$4.76T
$239K 0.1%
1,280
– –
AVGO icon
62
Broadcom
AVGO
$1.82T
$234K 0.09%
710
– –
LLY icon
63
Eli Lilly
LLY
$1.07T
$229K 0.09%
300
– –
PTHS
64
Pelthos Therapeutics
PTHS
$95.9M
$171K 0.07%
+6,112
New +$148K
QURE icon
65
uniQure
QURE
$2.63B
$117K 0.05%
+2,000
New +$36.3K
LEGH icon
66
Legacy Housing
LEGH
$628M
$110K 0.04%
4,000
– –
IVVD icon
67
Invivyd
IVVD
$180M
$110K 0.04%
+100,000
New +$88.7K
IWR icon
68
iShares Russell Mid-Cap ETF
IWR
$56.1B
$99K 0.04%
+695
New +$65.9K
EBC icon
69
Eastern Bankshares
EBC
$5.29B
$90.8K 0.04%
5,000
– –
URI icon
70
United Rentals
URI
$70.2B
$74.5K 0.03%
78
– –
PWR icon
71
Quanta Services
PWR
$93.1B
$72.9K 0.03%
176
– –
GOOGL icon
72
Alphabet (Google) Class A
GOOGL
$3.99T
$72.9K 0.03%
300
– –
TTE icon
73
TotalEnergies
TTE
$187B
$71.6K 0.03%
1,200
– –
AMZN icon
74
Amazon
AMZN
$2.49T
$65.9K 0.03%
300
– –
BRSL
75
Brightstar Lottery PLC
BRSL
$1.93B
$43.1K 0.02%
2,500
– –
1 2
3
4

Similar funds

DI
Disciplined Investors Waco, Texas $168M AUM 23.6% 1-Year Est. Return
WFS
Widmann Financial Services Bowie, Maryland $168M AUM 24.36% 1-Year Est. Return
CCG
Catalina Capital Group Torrance, California $168M AUM 16.69% 1-Year Est. Return
7CM
7G Capital Management New York $168M AUM 45.68% 1-Year Est. Return
MAG
Meadowbrook Advisors Group Bedminster, New Jersey $168M AUM
PFA
Presper Financial Architects Akron, Ohio $168M AUM 12.94% 1-Year Est. Return
CW
Code Waechter Tampa, Florida $168M AUM 15.56% 1-Year Est. Return
IWA
Integrity Wealth Advisors Ventura, California $168M AUM 18.33% 1-Year Est. Return

David M. Knott Jr's Q3 2025 Portfolio in Review

As of Q3 2025, David M. Knott Jr held 98 positions worth $248M, up 12% from $221M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

David M. Knott Jr's Q3 2025 filing shows 13 new, 15 increased, 10 reduced and 10 closed positions. Its largest new stake was Rezolute: 275,000 shares worth $2.58M. The largest sale was Calumet Specialty Products, an estimated $7.4M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Materials and Financials.

  • David M. Knott Jr's largest Q3 2025 buy was Rezolute: 275,000 shares worth $2.58M.
  • David M. Knott Jr added most to Syndax Pharmaceuticals in Q3 2025, an estimated $985K increase.
  • David M. Knott Jr's biggest Q3 2025 reduction was Calumet Specialty Products, cutting an estimated $7.4M.
  • David M. Knott Jr fully exited Inozyme Pharma in Q3 2025, selling an estimated $2.66M.
  • David M. Knott Jr's ten largest holdings make up 70% of its $248M portfolio in Q3 2025.
  • David M. Knott Jr opened 13 new positions and closed 10 in Q3 2025.
  • David M. Knott Jr's portfolio value rose 12% quarter-over-quarter to $248M.

Based on David M. Knott Jr's 13F filing for Q3 2025, filed 12 Nov 2025.